BBI Solutions, a world leader in immunoassay development and contract manufacturing, will launch its unique range of Recombinant Fab Monoclonal Antibodies on booth #3363 at the American Association for Clinical Chemistry’s (AACC) Annual Meeting and Clinical Lab Expo, on July 28-August 31, 2013, in Houston, Texas.

These matched antibodies pairs, developed using proprietary phage display selection and the Luminex platform, exhibit sub-nanomolar affinities, exceptional sensitivity, and provide assay developers with clinically relevant performance characteristics to 34 biomarkers, with more in development.

The new Recombinant Fab Mouse Monoclonal Antibodies from BBI Solutions exhibit significant advantages over standard mouse monoclonal antibodies.  From the screening process to testing in patient samples to ensure clinical significance, BBI Solutions’ methodology ensures that companies developing new assays have the most sensitive and reliable antibodies available in the market.

Because these new antibodies are grown in and purified from E. coli cultures, production is much quicker and more reliable than standard cell culture techniques, and large scale production is not an issue.

In regard to the new range, Dr. James Steggles, Commercial Manager at BBI Solutions, says, “Here at BBI Solutions it is our aim to ensure that we supply the market with antibodies that have world-class performance and give our customers significant advantages over their competitors.  Each antibody pair is the best from a billion clones screened and 4500 matched pairs tested.  By using this new range of monoclonal antibodies, they can produce clinical assays that are more sensitive and reliable than their competitors, as well as more cost-effective due to reduced R&D costs.”

BBI Solutions scientists will be at the AACC Conference to discuss the development of new products and any specific requirements customers may have. 

more about Recombinant Fab Monoclonal Antibodies

more about BBI Solutions